Long Read Sequencing Market projected to reach USD 2,514.3 Million by 2030, growing at a CAGR of 26.4% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study

The Global Long Read Sequencing Market was valued USD 487.7 Million in 2023 and projected to reach USD 2,514.3 Million by 2030, growing at a CAGR of 26.4% during the forecast period of 2023-2030

Richmond, Feb. 20, 2024 (GLOBE NEWSWIRE) -- According to a research report "Long Read Sequencing Market, by Technology (Single Molecule Real Time Sequencing, Nanopore Sequencing, Others), Application (Whole Genome Sequencing, Targeted Sequencing, Metagenomics, RNA Sequencing, Others) End Use (Academic & Research Institutes, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others), and Region - Global Forecast to 2030.

Global Long Read Sequencing Market Report Scope:

Report Details
Market size value in 2023 USD 487.7 Million
Market size value in 2030 USD 2,514.3 Million
CAGR (2023-2030) 26.4%
Forecast Period 2023–2030
Historic Data 2019
Forecast Units Value (USD Million/USD Billion)
Segments Covered Technology, Application, End User and Region
Geographies Covered North America, Europe, Asia Pacific, and RoW
  • Garvan Institute of Medical Research
Sample of Companies Covered
  • Eurofins Genomics
  • F. Hoffmann-La Roche Ltd

Download the Sample - https://www.marketdigits.com/request/sample/4154

TOC Covers in Depth & Breath on Long Read Sequencing Market
170 - Market Data Tables
65 - List of Figures
225 – Pages

The report includes Vendor Assessment (Company Profiles, Market Positioning, Strategies, Recent Developments, Capabilities & Product Offerings / Mapping), Technology Assessment (Developments & Economic Impact), Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional FootPrint by MarketDigits.

Market Overview

The long-read sequencing (LRS) market is witnessing significant growth driven by the need to overcome limitations associated with short-read sequencing (SRS). LRS, offering reads exceeding 10,000bp, beats SRS in genome assembly, particularly in addressing challenges posed by repetitive sequences. The dominance of true LRS technologies, exemplified by Pacific Biosciences and Oxford Nanopore Technologies (Nanopore), marks a withdrawal from conventional short-read systems. Inherent benefits drive the market, with longer reads facilitating improved genome assembly, enhanced variant detection, and efficient haplotype phasing. PacBio and Nanopore's real-time sequencing capabilities, coupled with portability, offer a competitive edge. Nanopore's devices, detecting electronic signals, are compact and portable, enabling field applications during outbreaks. Rapid sequencing, with PacBio completing runs in <24 hours, and user-determined run times by Nanopore, enhances flexibility and eliminates batch sequencing requirements, particularly advantageous for small genomes and specific genomic regions. Beyond genomics, LRS's foray into other 'omics realms, such as direct RNA sequencing and simultaneous detection of epigenetic modifications, broadens market opportunities. While LRS holds promise for diagnosing diseases, challenges and limitations persist, requiring careful consideration. The market's trajectory hinges on overcoming these challenges to harness the full potential of LRS in clinical sequencing and disease understanding.

Major vendors in the global Long Read Sequencing market are

  • BGI
  • Eurofins Genomics
  • F. Hoffmann-La Roche Ltd
  • Garvan Institute of Medical Research
  • Illumina, Inc.
  • MicrobesNG
  • Oxford Nanopore Technologies plc.
  • PacBio
  • Quantapore, Inc.
  • Other notable players

Direct Order Can Be Placed Through This Link and Get 25% Discount on Premium Report: https://www.marketdigits.com/checkout/4154?lic=s

Rising Demand for Whole Genome Reconstruction

One of the primary drivers for the global Long Read Sequencing market is the growing demand for whole genome reconstruction is boosting the importance of long-read sequencing (LRS) in the market. Unlike short-read sequencing (SRS), LRS, demonstrated by PacBio and Oxford Nanopore, offers accelerated sequencing runs, completing analyses in less than 24 hours. This swift turnaround is vital in meeting the rising demand for comprehensive genome assembly, as LRS provides considerably longer reads, simplifying the difficult task of piecing together the complex human genome. The flexibility and real-time capabilities of Nanopore technologies cater to the dynamic requirements of whole-genome reconstruction. LRS addresses the challenges posed by repetitive genomic regions and large-scale rearrangements, enhancing the accuracy of reconstruction and closing gaps in genomic knowledge. As the healthcare and research sectors increasingly prioritize in-depth genomic insights, the speed, flexibility, and extended read lengths of LRS position it as a pivotal technology meeting the escalating demand for whole genome reconstruction.


  • Ongoing advancements in long-read sequencing technologies
  • Long-read sequencing facilitates more accurate and comprehensive genomic data generation Clinical Applications and Precision Medicine
  • Rising Demand for Whole Genome Reconstruction


  • The portability of some LRS platforms, such as Nanopore's devices, presents an opportunity for on-site and field applications
  • The benefits of utilizing longer reads for genome reconstruction and analysis can significantly  impact the diagnosis of diseases and disorders
  • Real-Time Sequencing and Speed
  • Expansion to Other 'Omics

Real-Time Sequencing and Speed

In contrast to the predetermined run durations of Short-Read Sequencing (SRS) systems, both PacBio and Oxford Nanopore offer accelerated sequencing processes. PacBio provides options for swift sequencing, allowing completion within less than 24 hours, spanning from sample preparation to analysis. Nanopore technologies enable real-time analyses, empowering users to determine the experimental run time, facilitating tracking of data collection, and initiating analyses at their convenience. This flexibility and speed eliminate the necessity for batch sequencing of multiple samples, a requirement for cost-effective SRS. This capability is particularly advantageous when scrutinizing small genomes, such as those found in many pathogens, or specific genomic regions.

North America dominates the market for Long Read Sequencing.

North America leads the long-read sequencing market, driven by substantial investments in cutting-edge genomics technologies. The region's advanced healthcare infrastructure, research initiatives, and collaborations with key industry players contribute to its market dominance. Continuous technological advancements, coupled with a strong demand for precision medicine, further propel the growth of long-read sequencing solutions in North America.

In Asia Pacific, particularly Japan, the long-read sequencing market experiences dynamic regional trends. Rising investments in advanced diagnostic techniques and major players establishing a robust presence contribute to the region's growth. Japan, with a flourishing genomics industry, emerges as a key market driven by the demand for precision medicine and a deeper understanding of genetics. As Japan continues to advance in genomics research and technology, the long-read sequencing market in the Asia Pacific, especially in Japan, is ready for significant expansion.

The Whole Genome Sequencing Segments is anticipated to hold the Largest Market Share during the Forecast Period

In the global Long Read Sequencing market, the application segment comprises various categories such as Whole Genome Sequencing, Targeted Sequencing, Metagenomics, RNA Sequencing, and Others. The Whole Genome Sequencing (WGS) segment in the long-read sequencing market is pivotal for genomics research, offering a comprehensive analysis of entire genomes. Commonly employed in studying human genomes, the scalability and flexibility of next-generation sequencing (NGS) technology extend its utility to various species, including livestock, plants, and disease-related microbes. WGS provides a high-resolution, base-by-base perspective of the genome, enabling the capture of both large and small variants often overlooked by targeted approaches. This approach proves instrumental in identifying causative variants for subsequent studies on gene expression and regulation mechanisms. The ability of WGS to deliver substantial data swiftly supports the assembly of novel genomes, making it a powerful tool in genomics research with broad applications in diverse fields, from understanding inherited disorders to tracking disease outbreaks.

Inquire Before Buying: https://www.marketdigits.com/request/enquiry-before-buying/4154

Browse Similar Reports:

MiRNA Sequencing and Assay Market 2030 By Type, Distribution Channel, End-user and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints by MarketDigits

Clinical Oncology Next-generation Sequencing Market 2030 By Type, Distribution Channel, End-user and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints by MarketDigits

mRNA Sequencing Market 2030 By Type, Distribution Channel, End-user and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints by MarketDigits

About MarketDigits:

MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

We offer services that are most relevant and beneficial to the users, which help businesses to sustain themselves in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.

Contact Us:
1248 CarMia Way Richmond,
VA 23235,
United States.
USA: +1 847 450 0808
Email: sales@marketdigits.com
Web: https://www.marketdigits.com
Follow Us on: | Twitter | LinkedIn |